TTM
$16.7B
YoY change
+26.5%
5Y CAGR
+5.4%
Peak year (FY2025)
$16.9B
Cumulative EBITDA
$237B
EBITDA history chart for Amgen (AMGN) from 2016 to 2025
Latest: $16.9B
EBITDA growth chart for Amgen (AMGN) from 2016 to 2025
Latest: +26.5%
EBITDA history table for Amgen (AMGN) from 1985 to 2025
| FY2025 | $16.9B | +26.5% | +$3.54B | ||
| FY2024 | $13.4B | -9.8% | -$1.45B | ||
| FY2023 | $14.8B | +21.6% | +$2.63B | ||
| FY2022 | $12.2B | +7.7% | +$873M | ||
| FY2021 | $11.3B | -13.1% | -$1.7B | ||
| FY2020 | $13B | +2.9% | +$363M | ||
| FY2019 | $12.6B | -1.9% | -$250M | ||
| FY2018 | $12.9B | +0.2% | +$27M | ||
| FY2017 | $12.9B | +2.6% | +$328M | ||
| FY2016 | $12.5B | +12.0% | +$1.35B | ||
| FY2015 | $11.2B | +27.8% | +$2.43B | ||
| FY2014 | $8.75B | +15.5% | +$1.18B | ||
| FY2013 | $7.57B | +5.9% | +$423M | ||
| FY2012 | $7.15B | +22.9% | +$1.33B | ||
| FY2011 | $5.82B | -16.1% | -$1.12B | ||
| FY2010 | $6.94B | +1.6% | +$107M | ||
| FY2009 | $6.83B | +2.9% | +$192M | ||
| FY2008 | $6.64B | +11.0% | +$658M | ||
| FY2007 | $5.98B | -0.9% | -$53M | ||
| FY2006 | $6.03B | +6.1% | +$345M | ||
| FY2005 | $5.69B | +22.7% | +$1.05B | ||
| FY2004 | $4.64B | +22.7% | +$858M | ||
| FY2003 | $3.78B | +42.4% | +$1.12B | ||
| FY2002 | $2.65B | +47.7% | +$857M | ||
| FY2001 | $1.8B | +13.7% | +$217M | ||
| FY2000 | $1.58B | +5.2% | +$78.1M | ||
| FY1999 | $1.5B | +19.0% | +$240M | ||
| FY1998 | $1.26B | +20.5% | +$215M | ||
| FY1997 | $1.05B | +3.1% | +$31.1M | ||
| FY1996 | $1.02B | +20.3% | +$171M | ||
| FY1995 | $845M | +9.3% | +$72M | ||
| FY1994 | $773M | +28.4% | +$171M | ||
| FY1993 | $602M | +13.2% | +$70.2M | ||
| FY1992 | $532M | +266.9% | +$387M | ||
| FY1991 | $145M | +110.6% | +$76.1M | ||
| FY1990 | $68.8M | — | — | ||
| FY1988 | $3.2M | -313.3% | +$4.7M | ||
| FY1987 | -$1.5M | -225.0% | -$2.7M | ||
| FY1986 | $1.2M | -25.0% | -$400K | ||
| FY1985 | $1.6M | — | — |
- FY2025$16.9B+26.5%
- FY2024$13.4B-9.8%
- FY2023$14.8B+21.6%
- FY2022$12.2B+7.7%
- FY2021$11.3B-13.1%
- FY2020$13B+2.9%
- FY2019$12.6B-1.9%
- FY2018$12.9B+0.2%
- FY2017$12.9B+2.6%
- FY2016$12.5B+12.0%
- FY2015$11.2B+27.8%
- FY2014$8.75B+15.5%
- FY2013$7.57B+5.9%
- FY2012$7.15B+22.9%
- FY2011$5.82B-16.1%
- FY2010$6.94B+1.6%
- FY2009$6.83B+2.9%
- FY2008$6.64B+11.0%
- FY2007$5.98B-0.9%
- FY2006$6.03B+6.1%
- FY2005$5.69B+22.7%
- FY2004$4.64B+22.7%
- FY2003$3.78B+42.4%
- FY2002$2.65B+47.7%
- FY2001$1.8B+13.7%
- FY2000$1.58B+5.2%
- FY1999$1.5B+19.0%
- FY1998$1.26B+20.5%
- FY1997$1.05B+3.1%
- FY1996$1.02B+20.3%
- FY1995$845M+9.3%
- FY1994$773M+28.4%
- FY1993$602M+13.2%
- FY1992$532M+266.9%
- FY1991$145M+110.6%
- FY1990$68.8M—
- FY1988$3.2M-313.3%
- FY1987-$1.5M-225.0%
- FY1986$1.2M-25.0%
- FY1985$1.6M—
EBITDA values are taken from Amgen's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Amgen (AMGN)
According to Amgen's latest reported financial statements, the company's current EBITDA (TTM) is $16.7B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Amgen (AMGN) most recent annual EBITDA stands at $16.9B (2025) – grew 26.5% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Amgen EBITDA compounded at +5.4% per year, with mixed annual results across the window.
Across the available history, EBITDA reached its high of $16.9B in 2025 and its low of -$1.5M in 1987.
Amgen EBITDA by Year
Amgen EBITDA 2025: $16.9B
Amgen posted EBITDA of $16.9B in 2025, grew 26.5% from 2024. This figure represents the highest annual value in the available history.
Amgen EBITDA 2024: $13.4B
In 2024, Amgen reported EBITDA of $13.4B, declined 9.8% below 2023.
Amgen EBITDA 2023: $14.8B
Amgen EBITDA in 2023 was $14.8B, grew 21.6% from 2022.
Amgen EBITDA 2022: $12.2B
2022's EBITDA for Amgen came in at $12.2B, grew 7.7% from 2021.
Amgen EBITDA 2021: $11.3B
Amgen EBITDA in 2021 was $11.3B.
See more financial history for Amgen (AMGN).
Sector peers by EBITDA
Healthcare peers of Amgen (AMGN), ranked by their latest EBITDA
| $41.1B | |
| $28.3B | |
| $27.9B | |
| $24.4B | |
| $23.1B | |
| $17.6B | |
| $11.6B | |
| $11.5B |
- $41.1B
- $28.3B
- $27.9B
- $24.4B
- $23.1B
- $17.6B
Frequently asked questions
Amgen (AMGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks
- Dividend Profile2.53% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History5 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.